One protein, two phosphorylation sites, opposite answers

DARPP-32 is the best-documented case in neuroscience of a single protein working as a bidirectional signal integrator. Phosphorylated on threonine 34 it shuts down a phosphatase; phosphorylated on threonine 75 it shuts down a kinase instead. The ratio between those two sites is how a striatal neuron reports what it has just been told.

A protein found by looking for what dopamine does next

By the early 1980s dopamine receptors were known, and cAMP was known to be a second messenger downstream of them. What was missing was the substrate — the protein that actually changed when a dopamine signal arrived.

Walaas and Greengard found it by mapping phosphoproteins against dopaminergic innervation. A protein of apparent molecular weight 32,000 tracked the dopamine map almost exactly, was most concentrated in the basal ganglia, and became phosphorylated in intact caudatoputamen tissue in response to dopamine and to 8-bromo-cAMP ¹. Critically, it sat in the neurons that receive dopamine, not the ones that release it. They named it DARPP-32: dopamine- and cAMP-regulated phosphoprotein, 32 kDa ¹. The companion immunocytochemical paper placed it in cell bodies and dendrites throughout the caudatoputamen, nucleus accumbens, and olfactory tubercle, and in presumed nerve terminals in their targets — globus pallidus, entopeduncular nucleus, and substantia nigra pars reticulata — while finding none in the dopaminergic neurons themselves ².

The function fell out of a resemblance. Purified DARPP-32 looked physically and chemically like phosphatase inhibitor-1. So Hemmings, Greengard, Tung, and Cohen tested it as one, and it inhibited protein phosphatase-1 at nanomolar concentrations — but only in its phosphorylated form ³. Sequencing the bovine protein later placed the PKA-phosphorylated threonine at position 34 and showed that the molecule is in fact a 202-residue chain of about 22.6 kDa ⁴. It runs at 32 kDa on SDS-PAGE because it is very hydrophilic and contains a stretch of 16 consecutive acidic residues, not because it is that large. Anyone blotting for it should expect the band where the name says, and should not read the gel mobility as a mass measurement. The gene is now PPP1R1B ⁵.

This work belongs to the research program for which Paul Greengard shared the 2000 Nobel Prize in Physiology or Medicine, awarded jointly to Arvid Carlsson, Greengard, and Eric Kandel for discoveries concerning signal transduction in the nervous system ²⁶. Greengard's share was the demonstration that neurotransmitters act through receptor-mediated phosphorylation and dephosphorylation of brain proteins — and DARPP-32 was the substrate that made the case ²⁶.

Why inhibiting a phosphatase is the same thing as amplifying a kinase

The Thr34 arm runs like this. Dopamine binds a D1 receptor, a stimulatory G protein activates adenylyl cyclase, cAMP rises, PKA is released, and PKA phosphorylates DARPP-32 at Thr34 ⁶⁷. Phospho-Thr34 DARPP-32 is then a potent inhibitor of protein phosphatase-1 ³.

That last step is the one worth sitting with. Phosphorylation is a balance, not a switch: every phosphosite in the cell is simultaneously being written by kinases and erased by phosphatases, and the steady-state occupancy is set by the ratio of the two rates. Protein phosphatase-1 is the dominant eraser for a large share of PKA's targets in these neurons. So when PKA phosphorylates Thr34, it does not simply add one more phosphate to one more substrate — it disables the enzyme that would otherwise remove phosphates from all its other substrates ⁶. A single kinase event propagates as a general, cell-wide increase in the persistence of PKA-driven phosphorylation. Mechanistically it is inhibition; functionally it is gain and duration. This is the feed-forward step that makes a transient dopamine event into a sustained biochemical state, and it is why DARPP-32 is described as an amplifier rather than just a substrate.

The consequences of removing it are not subtle. Mice with a targeted disruption of the DARPP-32 gene show deficits across molecular, electrophysiological, and behavioral responses to dopamine, to drugs of abuse, and to antipsychotic medication ⁸.

The other site, and the other direction

In 1999 Bibb and colleagues showed that the same protein carries a second, opposing switch. Cdk5 phosphorylates DARPP-32 at Thr75, and phospho-Thr75 DARPP-32 is a competitive inhibitor of PKA ⁹. Reducing phospho-Thr75 in striatal slices — with a Cdk5 inhibitor or in genetically altered mice — increased dopamine-induced phosphorylation of PKA substrates and increased peak voltage-gated calcium currents ⁹. One molecule, two threonines, a phosphatase inhibitor at one and a kinase inhibitor at the other.

The two arms are wired together. In resting striatal slices Cdk5 keeps Thr75 phosphorylated, which holds PKA down. Dopamine acting at D1 receptors, and acute cocaine in whole animals, decrease Thr75 phosphorylation and remove that constraint — and the mechanism is increased protein phosphatase-2A activity rather than any change in Cdk5 ¹⁰. PKA, once activated, de-inhibits itself. D2 stimulation does the reverse ¹⁰. The two kinase systems are mutually antagonistic, and the pathway behaves less like a linear cascade than like a switch with hysteresis ⁵.

Cdk5 is itself under transcriptional control by drug exposure: chronic cocaine and ΔFosB overexpression raise striatal Cdk5 mRNA, protein, and activity, and Cdk5 inhibitors injected into striatum potentiate the behavioral effects of repeated cocaine ¹¹. The Thr75 arm is where long-term adaptation writes itself onto acute signaling.

Where dopamine and glutamate meet

Thr34 is not only written by PKA; it is erased by calcineurin. Activation of NMDA receptors in rat striatal slices reverses cAMP-stimulated DARPP-32 phosphorylation through dephosphorylation, implicating the calcium-dependent phosphatase calcineurin (PP-2B) ¹². Dopamine and glutamate have opposite effects on the excitability of striatal neurons, and that antagonism is mirrored exactly in their opposite effects on a single residue of a single protein ¹².

The D2 arm uses the same machinery. D1 and D2 agonists have opposing effects on DARPP-32 phosphorylation; the D2 agonist quinpirole lowers basal and D1-stimulated phosphorylation, the effect is calcium-dependent and blocked by the calcineurin inhibitor cyclosporin A, and the D2 antagonist raclopride raises phosphorylation ¹³. Adenosine A2A receptors, which are functionally antagonistic to D2 receptors and are the target of caffeine, feed into the same node: caffeine's stimulant effect on motor activity is greatly reduced in DARPP-32 knockout mice, and caffeine raises Thr75 phosphorylation by inhibiting PP-2A-catalyzed dephosphorylation ¹⁴. Acute ethanol antagonizes D1-driven PKA phosphorylation of DARPP-32 and of the NMDA receptor NR1 subunit in vivo ¹⁵. Dopamine, glutamate, adenosine, and ethanol all converge on the phosphorylation state of one molecule ⁷.

The marker that identifies the cell

The striatum is built overwhelmingly from spiny GABAergic projection neurons; interneurons are a small fraction of total neuron number ¹⁶. DARPP-32 immunoreactivity is the standard way to identify those medium spiny neurons ²⁵.

Those neurons split into two output populations that express D1 and D2 receptors respectively and project to different targets — striatonigral and striatopallidal ¹⁷. DARPP-32 alone does not distinguish them; it is present in both, which is precisely why transgenic reporter approaches were needed to read phosphorylation separately in each. When Bateup and colleagues built BAC transgenic mice allowing DARPP-32 phosphorylation to be measured selectively in striatonigral versus striatopallidal neurons, cocaine and the antipsychotic haloperidol turned out to have opposite effects in the two populations — which accounts for their opposing behavioral effects, and which bulk striatal measurement had been averaging away ¹⁸.

The marker use is also a growing applied market. Directed differentiation protocols report yield as the proportion of DARPP-32-positive neurons produced; human embryonic stem cell-derived forebrain GABA neurons transplanted into quinolinic acid-lesioned mice generated large DARPP-32-positive populations that projected to substantia nigra and corrected locomotor deficits ¹⁹. For anyone building striatal neurons from stem cells, DARPP-32 immunoreactivity is the identity assay.

Disease

In Huntington's disease the medium spiny neuron is the cell that dies. In transgenic HD model mice, presymptomatic animals already show severe striatal dopamine signaling deficits, including selective reductions in total DARPP-32 and in other dopamine-regulated phosphoprotein markers of medium spiny neurons, alongside defects in the D1/DARPP-32 cascade itself ²⁰. DARPP-32 loss is an early readout of medium spiny neuron dysfunction, not a late one.

Other lines converge. In L-DOPA-induced dyskinesia, genetic inactivation of DARPP-32 reduces dyskinesia, and sensitized cAMP/PKA/DARPP-32 signaling drives ERK1/2, MSK-1, and histone H3 phosphorylation in medium spiny neurons ²¹. In humans, a frequent PPP1R1B haplotype predicts isoform mRNA expression in postmortem brain, is associated with performance on frontostriatal cognitive tests and with neostriatal volume, activation, and prefrontal functional connectivity, and was associated with schizophrenia risk in one family-based analysis ²².

What the antibodies actually let you do

Total DARPP-32 answers one question: is this cell a medium spiny neuron. It is a good answer — the protein is abundant, its distribution is well characterized, and it works in immunohistochemistry, immunofluorescence, and Western blot ². But it is a census, not a measurement of activity. Total protein does not move on the timescale of a drug injection.

Phospho-Thr34 and phospho-Thr75 answer the other question: what signal did this cell just receive. And they must be read together. The mechanism is reciprocal — PKA activity lowers Thr75 while raising Thr34 ¹⁰ — so an experiment that measures only one site cannot distinguish a change in signaling from a change in the other arm. The interpretable quantity is the ratio, normalized to total DARPP-32 on the same samples. Phospho-specific antibodies of this class are typically used for immunoblotting of striatal lysates and for immunofluorescence on fixed tissue; phospho-epitope detection is generally more sensitive to fixation, antigen retrieval, and phosphatase inhibition in the lysis buffer than total-protein detection, so a total-protein blot that works is not evidence that the phospho-blot will.

Caveat — Do not measure DARPP-32 phosphorylation in tissue that was not quenched instantly. Kinases and phosphatases keep working after death, and the published standard for this protein is to kill the animal by focused microwave irradiation. The original in vivo assay measured basal phospho-DARPP-32 at 5.6% of total, rising to 44.4% after L-DOPA — and explicitly reported that the measured effect was smaller when focused microwave irradiation was not used ²³. Modern phospho-panel work in this pathway uses the same approach: animals killed instantly by focused microwave irradiation, then immunoblotted with phospho-specific antibodies ²⁴. Standard decapitation and dissection introduces a post-mortem interval during which the very quantity being measured is still being edited. If your protocol cannot quench instantly, say so in the methods and treat the absolute percentages as uninterpretable — report only within-experiment comparisons in which every animal received identical handling.

Choosing and reporting the reagent

The International Working Group for Antibody Validation set out five conceptual pillars — genetic strategies, orthogonal strategies, independent antibody strategies, tagged-protein expression, and immunocapture followed by mass spectrometry — applied in an application-specific way ²⁵. For this target the genetic pillar is unusually clean: DARPP-32 knockout mice exist and are well characterized ⁸, and for the phosphosites, pharmacological manipulation in striatal slices gives a bidirectional orthogonal control — a D1 agonist should raise Thr34 and lower Thr75, a D2 agonist should do the opposite ¹⁰¹³. Report catalog number, lot, host, the phosphosite, and your quench method; for this protein the quench method is part of the result.

Catalog no.	Antibody	Host
P40003	DARPP-32	Rabbit
P40004	Phospho-DARPP-32 (Thr34, PKA site)	Rabbit
P40005	Phospho-DARPP-32 (Thr75, Cdk5 site)	Rabbit

References

1. Walaas SI, Greengard P. DARPP-32, a dopamine- and adenosine 3':5'-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. I. Regional and cellular distribution in the rat brain. J Neurosci. 1984;4(1):84-98. doi:10.1523/JNEUROSCI.04-01-00084.1984 · PMID 6319627
2. Ouimet CC, Miller PE, Hemmings HC, Walaas SI, Greengard P. DARPP-32, a dopamine- and adenosine 3':5'-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. III. Immunocytochemical localization. J Neurosci. 1984;4(1):111-24. doi:10.1523/JNEUROSCI.04-01-00111.1984 · PMID 6319625
3. Hemmings HC, Greengard P, Tung HY, Cohen P. DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1. Nature. 1984;310(5977):503-5. doi:10.1038/310503a0 · PMID 6087160
4. Williams KR, Hemmings HC, LoPresti MB, Konigsberg WH, Greengard P. DARPP-32, a dopamine- and cyclic AMP-regulated neuronal phosphoprotein. Primary structure and homology with protein phosphatase inhibitor-1. J Biol Chem. 1986;261(4):1890-903. PMID 3511054
5. Girault JA, Nairn AC. DARPP-32 40 years later. Adv Pharmacol. 2020;90:67-87. doi:10.1016/bs.apha.2020.09.004 · PMID 33706939
6. Greengard P. The neurobiology of slow synaptic transmission. Science. 2001;294(5544):1024-30. doi:10.1126/science.294.5544.1024 · PMID 11691979
7. Svenningsson P, Nishi A, Fisone G, Girault JA, Nairn AC, Greengard P. DARPP-32: an integrator of neurotransmission. Annu Rev Pharmacol Toxicol. 2004;44:269-96. doi:10.1146/annurev.pharmtox.44.101802.121415 · PMID 14744247
8. Fienberg AA, Hiroi N, Mermelstein PG, et al. DARPP-32: regulator of the efficacy of dopaminergic neurotransmission. Science. 1998;281(5378):838-42. doi:10.1126/science.281.5378.838 · PMID 9694658
9. Bibb JA, Snyder GL, Nishi A, et al. Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature. 1999;402(6762):669-71. doi:10.1038/45251 · PMID 10604473
10. Nishi A, Bibb JA, Snyder GL, Higashi H, Nairn AC, Greengard P. Amplification of dopaminergic signaling by a positive feedback loop. Proc Natl Acad Sci U S A. 2000;97(23):12840-5. doi:10.1073/pnas.220410397 · PMID 11050161
11. Bibb JA, Chen J, Taylor JR, et al. Effects of chronic exposure to cocaine are regulated by the neuronal protein Cdk5. Nature. 2001;410(6826):376-80. doi:10.1038/35066591 · PMID 11268215
12. Halpain S, Girault JA, Greengard P. Activation of NMDA receptors induces dephosphorylation of DARPP-32 in rat striatal slices. Nature. 1990;343(6256):369-72. doi:10.1038/343369a0 · PMID 2153935
13. Nishi A, Snyder GL, Greengard P. Bidirectional regulation of DARPP-32 phosphorylation by dopamine. J Neurosci. 1997;17(21):8147-55. doi:10.1523/JNEUROSCI.17-21-08147.1997 · PMID 9334390
14. Lindskog M, Svenningsson P, Pozzi L, et al. Involvement of DARPP-32 phosphorylation in the stimulant action of caffeine. Nature. 2002;418(6899):774-8. doi:10.1038/nature00817 · PMID 12181566
15. Edwards S, Simmons DL, Galindo DG, et al. Antagonistic effects of dopaminergic signaling and ethanol on protein kinase A-mediated phosphorylation of DARPP-32 and the NR1 subunit of the NMDA receptor. Alcohol Clin Exp Res. 2002;26(2):173-80. PMID 11964556
16. Kreitzer AC. Physiology and pharmacology of striatal neurons. Annu Rev Neurosci. 2009;32:127-47. doi:10.1146/annurev.neuro.051508.135422 · PMID 19400717
17. Gerfen CR, Engber TM, Mahan LC, et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science. 1990;250(4986):1429-32. doi:10.1126/science.2147780 · PMID 2147780
18. Bateup HS, Svenningsson P, Kuroiwa M, et al. Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs. Nat Neurosci. 2008;11(8):932-9. doi:10.1038/nn.2153 · PMID 18622401
19. Ma L, Hu B, Liu Y, et al. Human embryonic stem cell-derived GABA neurons correct locomotion deficits in quinolinic acid-lesioned mice. Cell Stem Cell. 2012;10(4):455-64. doi:10.1016/j.stem.2012.01.021 · PMID 22424902
20. Bibb JA, Yan Z, Svenningsson P, et al. Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. Proc Natl Acad Sci U S A. 2000;97(12):6809-14. doi:10.1073/pnas.120166397 · PMID 10829080
21. Santini E, Valjent E, Usiello A, et al. Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci. 2007;27(26):6995-7005. doi:10.1523/JNEUROSCI.0852-07.2007 · PMID 17596448
22. Meyer-Lindenberg A, Straub RE, Lipska BK, et al. Genetic evidence implicating DARPP-32 in human frontostriatal structure, function, and cognition. J Clin Invest. 2007;117(3):672-82. doi:10.1172/JCI30413 · PMID 17290303
23. Lewis RM, Levari I, Ihrig B, Zigmond MJ. In vivo stimulation of D1 receptors increases the phosphorylation of proteins in the striatum. J Neurochem. 1990;55(3):1071-4. doi:10.1111/j.1471-4159.1990.tb04600.x · PMID 2166772
24. Snyder GL, Galdi S, Hendrick JP, Hemmings HC. General anesthetics selectively modulate glutamatergic and dopaminergic signaling via site-specific phosphorylation in vivo. Neuropharmacology. 2007;53(5):619-30. doi:10.1016/j.neuropharm.2007.07.008 · PMID 17826804
25. Uhlen M, Bandrowski A, Carr S, et al. A proposal for validation of antibodies. Nat Methods. 2016;13(10):823-7. doi:10.1038/nmeth.3995 · PMID 27595404
26. Gispen WH. [Nobel prize in physiology or medicine for year 2000 for research of signal transduction in the nervous system]. Ned Tijdschr Geneeskd. 2000;144(46):2184-7. PMID 11103253

Sourcing note. Primary literature located through PubMed; every quantitative figure was taken from the source article’s own record. Findings are reported at the grain of the study that produced them and those grains are not interchangeable. Product specifications are from the current Pel-Freez datasheets.